In 2012, pertuzumab (Perjeta®) was FDA approved for use with trastuzumab and docetaxel, a microtubule depolymerization inhibitor, for first-line therapy for HER2+ metastatic BC (mBC) [44]. The gene discussed is ERBB2; the disease is breast cancer.